PUBLISHER: Grand View Research | PRODUCT CODE: 1888788
PUBLISHER: Grand View Research | PRODUCT CODE: 1888788
The global preterm birth and PROM testing market size was estimated at USD 1.56 billion in 2024 and is projected to reach USD 3.26 billion by 2033, growing at a CAGR of 8.6% from 2025 to 2033. Increasing advancements in point-of-care diagnostics are expected to have a positive impact on the preterm birth and PROM testing market.
The increasing average age of pregnant women, leading to an exponential rise in the number of early births, and the delay in parenthood due to sociodemographic factors, including education/career goals, the growing impact of women's empowerment movements, and financial barriers, are key factors driving the adoption of tests in the market. According to research conducted by a group of researchers in Southern Ethiopia in December 2021, hypertension during pregnancy and a history of either abortion or cesarean section are the major causes of complications during childbirth. The study recommended that early identification tests and treatment can minimize the risk of premature rupture of fetal membranes. Other factors that raise the probability of PROM in pregnant women are low socioeconomic conditions, sexually transmitted infections, and cigarette smoking during pregnancy.
According to UNICEF, India accounts for 25.0 million births each year and witnesses the death of one child every minute, with the mortality rate due to premature birth at 35.0%. While substantial development in Special Newborn Care Units (SNCUs) has led to a decline in neonatal mortality, the socio-cultural barriers in healthcare access for female infants remain a major factor behind higher female premature deaths. However, India has witnessed a consistent reduction in child mortality rates, driven by initiatives prioritizing newborn and maternal safety.
Governments and regulatory bodies are taking considerable measures to increase access to PROM testing across several regions. For instance, in March 2022, Sera Prognostics Inc. announced that the Centers for Medicare & Medicaid Services established a Medicare payment rate of USD 750 for its PreTRM test, a proteomic blood test designed to measure preterm birth risk. The test has gained additional traction, with ongoing commercial collaboration between Sera and Elevance Health regarding coverage for its PreTRM test, which improves affordability for high-risk pregnant women and encourages broader adoption among hospitals and maternal-fetal medicine specialists.
Similarly, Actim PROM is a U.S. FDA-approved POC rapid test, to detect PROM. It provides rapid accurate results for preterm births. More than 7 million tests have been distributed in over 70 countries since they are highly reliable with 97% sensitivity and specificity. Actim Prom helps detect the protein biomarker Insulin-like Growth Factor Binding Protein-1 (IGFBP - 1). The advancements in POC diagnostics for PROM can encourage pregnant women to test for PROM more frequently when compared to a long procedure of testing held in hospitals and clinics.
Global Preterm Birth And PROM Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preterm birth and PROM testing market report based on type, application, and region: